DOYLESTOWN, Pa., June 19, 2017 – Bioclinica® eHealth Solutions, which provides an agile ecosystem and domain expertise for sponsors and CROs to speed clinical development, announced the launch of Clean Patient Optics™, a fully-validated clinical trial software solution that surfaces insights to patient data for accelerated database lock and clinical trial timelines. The product provides uninterrupted visibility into patient data status at the study, site, and patient level, empowering study teams to optimally focus the data cleaning process and remove obstacles that can create costly delays.
“Achieving database lock on time can be difficult, especially in larger trials with a vast amount of data to review and reconcile,” says Bioclinica’s eHealth Solutions Chief Technical Officer Andrew Masters. Clean Patient Optics is a technology-enabled solution for faster, easier and more efficient data cleaning and reconciliation. “Users apply insights to focus data cleaning, allowing the study team to meet or beat the database lock goal by days or even weeks.”
Moreover, Clean Patient Optics serves as an early warning system, signaling if a vendor is behind on making updates, or if a site is slow in reporting SAE information to the pharmacovigilance team. With powerful data visualization tools at their fingertips, study teams can uncover patterns and observations about the status of patient data external to the EDC system, such as ECG, Central Safety Lab and other important data requiring reconciliation, helping avoid surprises at the end of a study.
The entire study team benefits from Clean Patient Optics. Executive level personnel get answers about overall study health and team progress toward the database lock goal. Study managers, data managers and monitors see at a glance if a patient has reached the end of the study and any remaining data activities. They can quickly spot missing information, items to be reconciled, terms to be medically coded and pages to be source document verified. The benefits of implementing Clean Patient Optics for visibility into patient data cleaning include:
Clean Patient Optics is readily implemented as a companion product to Bioclinica’s Express® Electronic Data Capture (EDC) system and Data Management servicesâthe enterprise solution of choice for world-leading pharmaceutical companies and CROs.
“Our seamless solution provides sponsors and CROs unmatched capability to understand study health for accelerated clinical trial timelines,” Masters comments. Clean Patient Optics is another example of how Bioclinica continues to invest and innovate. “We’re pleased to deliver solutions in more areas of clinical development than any other technology provider, enabling organizations to see more clearly in their clinical research â and where it makes a real difference.”
Deployment is fast and easy on all new studies where Bioclinica’s Express EDC and Data Management solution are in use, requiring little time and effort to learn and use effectively. “All studies, no matter the size or therapeutic area, can benefit from Clean Patient Optics,” Masters adds.
Learn more online about Clean Patient Optics and Bioclinica Express, and read the Bioclinica blog and latest news on Bioclinica LinkedIn and Twitter channels.
About Bioclinica
Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized by three business segments to deliver focused service supporting multifaceted technologies. The Medical Imaging & Biomarkers segment provides medical imaging and cardiac safety services and includes a molecular marker laboratory. The eHealth Solutions segment comprises the eClinical Solutions platform; Randomization & Trial Supply Management; Financial Lifecycle Solutions; Safety & Regulatory Solutions; Strategic Consulting Services; App xChange Alliances; and eHealth Cloud Services. Under the Global Clinical Research segment, Bioclinica offers a network of research sites, patient recruitment services, and a post-approval research division. The Company serves more than 400 pharmaceutical, biotechnology and device organizations through a network of offices in the U.S., Europe, and Asia.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.